![dna-istock-518143098-ralwel--2](https://cdn.lifesciencesipreview.com/convert/files/2023/08/88d2bb40-4113-11ee-8179-0f0ce8051b03-dna-istock-518143098-ralwel--2.jpg/r%5Bwidth%5D=320/88d2bb40-4113-11ee-8179-0f0ce8051b03-dna-istock-518143098-ralwel--2.webp)
ralwel / iStockphoto.com
16 January 2018Europe
CRISPR opposition hearing kicks off at EPO
Today could play a pivotal role in the CRISPR patent landscape in Europe.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Biotechnology
27 October 2020 Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report.
Europe
30 November 2017 The Broad Institute of MIT and Harvard may lose a substantial number of European patent claims covering CRISPR/Cas9, but it has at least one trump card to play before we get to that stage, one European patent attorney has told LSIPR.
Europe
17 January 2018 The Broad Institute of Harvard and MIT has said it will appeal against a decision by the European Patent Office to revoke one of its patents covering CRISPR/Cas9 technology.
Editor's picks
Editor's picks
Europe
17 January 2018 The Broad Institute of Harvard and MIT has said it will appeal against a decision by the European Patent Office to revoke one of its patents covering CRISPR/Cas9 technology.
Europe
30 November 2017 The Broad Institute of MIT and Harvard may lose a substantial number of European patent claims covering CRISPR/Cas9, but it has at least one trump card to play before we get to that stage, one European patent attorney has told LSIPR.
Biotechnology
27 October 2020 Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report.
Europe
17 January 2018 The Broad Institute of Harvard and MIT has said it will appeal against a decision by the European Patent Office to revoke one of its patents covering CRISPR/Cas9 technology.
Europe
30 November 2017 The Broad Institute of MIT and Harvard may lose a substantial number of European patent claims covering CRISPR/Cas9, but it has at least one trump card to play before we get to that stage, one European patent attorney has told LSIPR.
Biotechnology
27 October 2020 Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report.